Clinical Psychology Department, Department of Psychiatry, Ponce Health Sciences University, Ponce, Puerto Rico.
Clinical Psychology Department, Department of Psychiatry, Ponce Health Sciences University, Ponce, Puerto Rico
BMJ Open. 2021 Mar 3;11(3):e041878. doi: 10.1136/bmjopen-2020-041878.
Among patients with cancer, depression is still under-detected. The use of technology-assisted screening tools is rising; however, little is known about the uptake of these devices as depression screening tools among patients with cancer.
A systematic review will be conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols (PRISMA-P). The review is registered with PROSPERO and any adjustments to the protocol will be traced. The aims of this systematic review are to (1) identify the most common and feasible depression screening information technology (IT) delivery models among patients with cancer, (2) identify the most common depression screening instrument used in IT devices and (3) describe the published technology-assisted depression screening tools for patients with cancer. PubMed, EBSCOhost and Google Scholar databases will be used. PICO (Patient/Population, Intervention, Comparison, Outcomes) guidelines will inform the inclusion criteria. Two researchers will independently review titles and abstracts, followed by full article review and data extraction. In the case of a disagreement, a third reviewer will make the final decision. Title/abstract screening will be conducted using a screening tool prepared by the researchers. Articles will be included for review if: (1) the study includes patients with cancer, cancer survivors and/or patients on remission, (2) depression is screened using technology and (3) technology-assisted depression screening effectiveness, efficacy, feasibility and/or acceptance is addressed. The quality of the articles will be assessed using the Methodological Index For Non-Randomised Studies (MINORS, maximum score 24) through independent coding of reviewers.
This research is exempt from ethics approval given that this is a protocol for a systematic review, which uses published data. Findings from this review will be disseminated through peer-reviewed publications and scientific conferences.
PROSPERO registration number CRD42019121048.
在癌症患者中，抑郁症仍然未被充分发现。使用技术辅助的筛查工具的情况正在增加；然而，对于这些设备作为癌症患者的抑郁症筛查工具的使用情况，我们知之甚少。
将使用系统评价和荟萃分析首选报告项目（PRISMA-P）进行系统综述。该综述已在 PROSPERO 上注册，任何对方案的调整都将被跟踪。本系统综述的目的是：(1) 确定癌症患者中最常见和最可行的抑郁症筛查信息技术 (IT) 传递模式；(2) 确定 IT 设备中最常用的抑郁症筛查工具；(3) 描述已发表的用于癌症患者的技术辅助抑郁症筛查工具。将使用 PubMed、EBSCOhost 和 Google Scholar 数据库。PICO（患者/人群、干预、比较、结果）指南将为纳入标准提供信息。两名研究人员将独立审查标题和摘要，然后进行全文审查和数据提取。如果存在分歧，将由第三名评审员做出最终决定。标题/摘要筛选将使用研究人员准备的筛选工具进行。如果符合以下标准，将纳入文章进行综述：(1) 研究包括癌症患者、癌症幸存者和/或缓解期患者；(2) 使用技术筛查抑郁症；(3) 评估技术辅助抑郁症筛查的有效性、疗效、可行性和/或可接受性。文章的质量将通过 reviewers 独立编码使用非随机研究方法学指数 (MINORS，最高得分为 24 分) 进行评估。
由于这是一项系统综述的方案，使用的是已发表的数据，因此该研究无需伦理批准。本综述的结果将通过同行评议的出版物和科学会议进行传播。
PROSPERO 注册号 CRD42019121048。
